Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: polar bear who wrote (25)	11/18/1997 11:47:00 PM
From: Luke	Read Replies (1) \| Respond to of 236

Hi P-Bear, No, there's no affiliation between the two. I've just recently seen a couple of articles discussing Pramod Srivastava's science at Antigenics and posted it becuse it seems to be interesting work in the same field. I thought they were in NY, but maybe not??? What sort of a job was the ad for? In short, I don't think they're exactly competitors. Stressgen among other things, has as it's most advanced project a fusion protein comprising a stress protein and a cancer antigen. I think this is to be used in a cervical cancer therapeutic vaccine first. I remember reading somewhere that they should give details about the first human trials in November, but this was a couple of months ago. Antigenics last reported on a "customized" vaccine, which is based on the idea that you can isolate stress proteins from a person's tumor, have associated with them the entire anigenic repertoire of that particular tumor, and then treat the person with this purified HSP mix. I gotta do some more reading as soon as I have time. I've seen a couple of good articles on the subject and I'll post them if I can dig 'em up again. later

To: polar bear who wrote (25)	11/19/1997 3:12:00 PM
From: William Marsh	Respond to of 236

Stressgen and Genzyme are partners. Stressgen's agreement with Genzyme is a good one - they split profits from any jointly developed products, which is better then a royalty agreement. Stressgen may be a supplier of stress protiens to Antigen. The experiments on mice referred to in the article are, I believe, the ones carried out for Gnezyme and Stressgen. The following is the 9/15/97 news release in which the experiments are described. StressGen/Genzyme LLC's gene therapy for cancer shown to have long-term survival benefit in early-stage research studies Findings presented at 3rd European Conference on Gene Therapy of Cancer Victoria, British Columbia - StressGen/Genzyme LLC announced today that new research studies conducted at the National Heart and Lung Institute in the UK confirm the ability of the Company's gene therapy technology to fight cancer. The studies, conducted in mouse models, show a 90% survival rate, of more than six months, in the study group treated with stress protein genes. In comparison, control animals receiving another foreign molecule, b-gal, survived an average of 35 days. The untreated group survived an average of 17 days. The new findings were presented last weekend in Berlin, Germany at the Third European Conference on Gene Therapy of Cancer by Dr. Katalin Lukacs, a co-inventor of the stress gene therapy approach. StressGen/Genzyme LLC, the recently announced joint venture company formed by StressGen Biotechnologies Corp., and Genzyme Molecular Oncology, a division of Genzyme Corp. of Cambridge, Mass., licensed this technology for use in the development of cancer therapies. The study was performed in a model of malignant mesothelioma, a fatal tumour often seen in patients after exposure to asbestos. The mouse model used in these experiments is very similar to human mesothelioma. The results of Dr. Lukacs' work showed three administrations of the liposome-complexed stress protein-65 gene (hsp65) were highly effective with 19 of 21 of the treated population alive six months after tumour initiation. These animals continue to be monitored. This survival data builds on earlier work by Dr. Lukacs and her team. In the April issue of Gene Therapy they published research that showed gene therapy technology can significantly regress tumours. They concluded that hsp65 could be an effective treatment in late stage cancer. Stress gene therapy technology was invented by Dr. Lukacs and Dr. Jo Colston of the Medical Research Council in the UK. Commenting on the latest results, StressGen Biotechnologies Corp.'s President and Chief Executive Officer, Richard M. Glickman said the study provides valuable information about the potential of stress gene therapy. "Dr. Lukacs' work is important as it further supports the belief that stress proteins may play an important role in unmasking cancer cells so that the immune system can see and attack them. Dr. Lukacs suggests hsp65 acts as a chaperone, working inside the cell to help process tumour antigens so that they can be transported to the cell surface and seen by the immune system. The increased presentation of tumour antigens on the cell surface is likely through MHC molecules. We know that antigen presentation by MHC molecules is crucial to immune recognition. If we can unmask cancer cells and make them easier for the immune system to identify, we will have a very powerful technology." The joint venture is using stress gene therapy to stimulate the body's immune system to fight cancer. This technology has the potential for wide application in the treatment of various types of cancer. Gene therapy is the introduction of a healthy or altered gene into the body to stimulate a particular response. The joint venture combines StressGen's proprietary approach for using stress protein genes to trigger the body's immune system to fight cancer with Genzyme's gene therapy vectors to deliver the therapeutic genes to cancer cells. The Canadian Medical Discoveries Fund, of London, Ontario has contributed $10 million in initial financing. Genzyme Corp., a biotechnology and health care products company, focuses on developing innovative products and services for major unmet medical needs. Genzyme Molecular Oncology develops molecular approaches to cancer diagnosis and therapy through genomics, gene therapy, genetic diagnostics, and a small-molecule combinatorial chemistry drug discovery program. Genzyme Molecular Oncology has its own common stock, which is not yet publicly traded, intended to reflect its value and track its performance. StressGen Biotechnologies Corporation is a biopharmaceutical company engaged in the research and development of stress proteins and stress protein genes for use in cancer treatments and vaccines to prevent infectious disease. The Company is also an international leader in the development, manufacture and sale of stress protein research biochemicals.